Medical device and drug sponsors may need to overenroll key patient populations under the US Food and Drug Administration’s new diversity action plan guidance, a move that could make the revamped clinical trial diversity push more challenging than anticipated.
Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups
New draft guidance on clinical trial diversity action plans pushes for disproportionately high enrollment of traditionally underrepresented groups, while also asking companies to tailor global programs to US populations and consider diversity aspects that Congress did not outline.
